CPA
NTLA icon

Capital Performance Advisors’s Intellia Therapeutics NTLA Stock Holding History

Capital Performance Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-106
Closed -$2.18K – 1817
2024
Q3 		$2.18K Buy
+106
New +$2.44K ﹤0.01% 1518

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's NTLA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 106 shares — an estimated $2.18K sold.

Capital Performance Advisors first reported a position in NTLA in Q3 2024 and held it in 1 quarter. The position peaked at $2.18K in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 106 Intellia Therapeutics shares in Q4 2024, an estimated $2.18K.
  • Capital Performance Advisors first reported a position in Intellia Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Intellia Therapeutics position peaked at $2.18K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.